Sigala C, Nelle H, Halabe J

Idioma: Español
Referencias bibliográficas: 33
Paginas: 212-215
Archivo PDF: 35.53 Kb.

FRAGMENTO

La talidomida se sintetizó por primera vez en el ańo de 1954 por los laboratorios Chemie Grünenthal, en Alemania, con el nombre molecular de alfa-phtalyglutamic-acid-imida. Conocida por sus efectos sedantes e hipnóticos, y utilizada en el tratamiento del vómito asociado al primer trimestre del embarazo, a mediados de los 50 era la tercera droga más vendida, sin toxicidad entonces reconocida, ya que fue probada en ratones a dosis 10,000 mg/kg sin observar efectos colaterales fatales.^1,2

REFERENCIAS (EN ESTE ARTÍCULO)

1. Powell RJ. New Roles for thalidomide: A unique anti-inflammatory, but use it only when no alternatives exist. BMJ 1996; 313(7054): 377-378.

2. George J, Elias S. Thalidomide and the Titanic: Reconstructing the technology tragedies of the Twentieth Century. Am J Public Health 1999; 89(1): 98-101.

3. Leslie H. Talidomida: Polémica y potencial. SF AIDS Fdn 1998; 5(98): 1-6.

4. Sampaio EP, Sarno EN, Galilly R et al. Thalidomide selectively inhibits tumor necrosis factor (alpha) production by stimulated human monocytes. J Exp Med 1991; 173: 699-703.

5. Barnhill RL, Doll NJ, Millikan LE et al. Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes. J Am Acad Dermatol 1984; 11: 814-819.

6. Vanchieri C. Preparing for thalidomide’s comeback. Ann Int Med 1997; 127(10): 951-952.

7. Corral LG, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 1999; 58(1): 1107-1113.

8. Meierhofer C, Dunzendorfer S, Wiedermann CJ. Protein kinase Cdependent effects on leukocyte migration of thalidomide. The J Infect Dis 1999; 180(1): 216-232.

9. Sheskin J. Thalidomide in the treatment of leprosy reactions. Clin Pharmacol Ther 1965; 6: 303-306.

10. Sheskin J. The treatment of leprosy reaction in lepromatous leprosy. Int J Derm 1980; 30: 318-21.

11. Elizabeth P, Sampaio, Kaplan G, Miranda A, Nery J, Sarno N et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993; 168: 408-414.

12. Iyer C, Languillon J, Ramanujam K, Tarabani-Castellani G, Terencio de las Aguas J et al. Who co-ordinated short-term double-blind trial with thalidomide in the treatment of acute leprosy reactions in male lepromatous patients. Bull Org mond. Santé 1971; 45: 719-732.

13. Sarno EN, Grau GE, Vieira M, Nery J. Serum levels of tumours necrosis factor-alpha and interleukin-1B during leprosy reactional states. Clin Exp Immunol 84: 103-108.

14. Barba-Rubio J, Franco-González F. Lupus eritematoso discoide y talidomida. Dermatología Rev Mex 1975; 19: 131.

15. Knop J, Happle R, Bonsman G et al. Treatment of lupus erythematosus profoundus with thalidomide. Arch Dermatol Res 1981; 280: 299.

16. Knop J, Happle R et al. Treatment of chronic discoid lupus erythematosus with thalidomide. Arch Dermatol Res 1981; 271: 165.

17. Naafs B, Bakkers EJM, Flinterman J et al. Thalidomide treatment of subacute cutaneous lupus erythematosus. Br J Dermatol 1982.

18. Walchner, Monika M, Michael M, Plewig G et al. Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus. Int J Dermatol 2000; 39(5): 383-388.

19. Grosshans E, Genevieve I. Thalidomide therapy for inflammatory dermatoses. Int J Dermatol 1984; 24: 598-602.

20. Jorizzo JL, Schmalstieg FC, Solomon AR et al . Thalidomide effects in Behçet’s syndrome and pustular vasculitis. Arch Intern Med 1986; 146: 878-881.

21. Hamuryudan V, Cem M, Saip S, Özyazgan Y, Siva A et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet,s Syndrome. Ann Intern Med 1998; 128: 443-450.

22. Revuz J, Guillaume JC, Janier M et al. Crossover study of thalidomide vs Placebo in severe recurrent apthous Stomatitis. Arch Dermatol 1990; 126: 923-926.

23. Van der Brock H. Treatment of prurigo nodularis with thalidomide. Arch Dermatol 1980; 116: 571-572.

24. Scott M, Peter J, Robert J, McGarr J et al. Use of thalidomide in treatment and maintenance of idiopathic Esophageal ulcers in HIV+individuals. Digestive Disease and Sciences 1995; 40(5): 1147-1148.

25. Youle M, Clarbour J, Farthing C et al. Treatment of resistant apthous ulceration with thalidomide in patients positive for HIV antibody. Br Med J 1989; 289: 432.

26. Haftel H, McCune J et al. Thalidomide to treat esophageal ulcer in AIDS. NEJM 1992; 16: 208.

27. Grunfeld C, Feingold K. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. NEJM 1992; 327(5): 329-335.

28. Reyes-Terna G, Sierra-Madero J, Martínez V, Arroyo-Figueroa H et al. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS 1996; 10: 1501-1507.

29. Sharpstone D, Rowbottom A, Nelson M, Lepper M, Gazzard B. Faecal tumour necrosis factors-alpha in individuals with HIV-related diarrhea. AIDS 1996; 10: 989-994.

30. Arend W, Dayer M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis and Rheumatism 1995; 38(2): 151-157.

31. Huizinga T, Dijkmans B, Van der Velde E, Van de Puw Krann T et al. An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. Ann Rheum Dis 1996; 55(1): 833-836.

32. Vogelsang G, Farmer E, Hess A, Altamonte V et al. Thalidomide for the treatment of chronic graft-versus-host disease. NEJM 1992; 326(16): 1055-1058.

33. Norfolk H, Bailey W et al. Thalidomide treatment for chronic graft-versus. Host disease. British Journal of Haematology 1991; 78: 23-227.